4 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: December 21, 2023
As we reach the end of 2023 and yet another remarkable year at Cleerly, it’s a great opportunity to reflect on all we’ve accomplished and begin planning for 2024. At Cleerly, we’ve always believed in pushing the boundaries of cardiovascular...
Read More »
3 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: September 19, 2022
Myocardial perfusion, also known as a "stress test", is today's go-to-method for detecting coronary artery disease - despite limited performance.
3 min read
Last week, our team at Cleerly had the opportunity to take part in a gathering of impassioned cardiac computed tomography (CT) leaders at the Society...
2 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: April 15, 2022
New research proposes a four-stage system for measuring the progression of cardiovascular disease (CAD) based on atherosclerotic plaque - not...
4 min read
Cleerly is excited to have released our vision statement calling for a new approach to cardiovascular care. It's an important topic - not just for...
4 min read
Cleerly is excited to have released our vision statement calling for a new approach to cardiovascular care. It's an important topic - not just for...
4 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: January 28, 2022
Historically, our diagnostic approaches to patients with suspected heart disease have been restricted to the evaluation of patients with symptoms...
